FORM PTO-1449			ATTORNEY DOCKET NO.		SERIAL NO).	
	Patent and Tr Office	ademark	4012-113 DIV2	09/430,735			
SUPPLEMENTAL INFORMATION		APPLICANT (5)74503,755					
	OSURE STATEM					•	
			Ekwuribe et al.		CROUD		
(use se	veral sheets if neces	ssary)	FILING DATE		GROUP		
			October 29, 1999		1018 11	,39	
		U.S.	PATENT DOCUMENTS		·		
EXAMINER	PATENT	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
INITIAL	NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS		
			(010)				
			012		1		
			JAN 22 S				
			JAN 27 2000 ST				
			A ADEMARK OFF				
				<u> </u>	<u> </u>		
	DOCUMENT	FOREI PUBLICATION	GN PATENT DOCUMENTS		 	TRANSI	ATION
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
				 	<u> </u>		ļ <u> </u>
						_	
				-			
							-
				<u></u> _		L	
	OTHER DOCU	JMENTS (Inclu	ding Author, Title, Journal-D	ate, Page N	l Paviou in Th	aranautic	Drug
AL A	A Delgado et al.	as, $9(3, 4)$:249-30	roperties of PEG-Linked Proteir	is . Critica	i Keview in 1 n	ier apearic i	Dr ug
	Currier Bystem	13, 7(3, 4).217 30					
							
						;	
							
		. —					
							
 							
			Continue on Page				
EVAMPLED				DATEC	ONSIDERED		
EXAMINER	la	N					
	p. cus				-bilo3	. lina slane	- ch
EXAMINER: In	nitial if citation cons conformance and n	sidered, whether ot considered. Ir	or not citation is in conformance nclude copy of this form with ne	e with MPE xt commun	ication to the	v iine inrou applicant.	

1

		<u> </u>		THE PARTY OF THE P	CERIAL NO		
FORM PTO-1449 US Dept. of Commerce			ATTORN	EY DOCKET NO.	SERIAL NO.		
Patent and Trademark Office		Patent and Trademark Office	4010	DIVO	09/430,735		
			4012-113 DIV2				
INFORMATION DISCLOSURE STATEMENT			APPLICA				
INFORMATI	un DIS	CLUSURE STATEMENT	Ekwuribe	اع مرد ا	T		
(use	e severa	l sheets if necessary)	FILING D		GROUP		
			October	29, 1999	1639		
			<u> </u>	DEMARK OFF	1 12 0 1		
		THER DOCUMENTS (Includ	ing Author		(umber, Etc.)		
7.1	CM	Pardridge W.M. "Plood Prain	Barrier Der	otide Transport and Pentide Dr	rug Delivery to the Brain," Amer.		
W	CM e	Chem Soc. 1995: 265-296.	Same of the	ranoport and repetite Di			
	CN	Pardridge, W.M., "CNS Drug D	esign Based	d on Principles of Blood-Brain	Barrier Transport," J.		
\ \	61	Neurochem., 1998, 70 (5): 178	1-1792.				
- 	CO 6	Pardridge, W.M., "New Approa	ches to Dru	g Delivery Through the Blood	-Brain Barrier," Trends in		
		Biotechnology, 1994: 239-245.					
	CP &	Prokai-Tatrai, K., et al., "Brain-		elivery of a Leucine-Enkephal	in Analogue by Retrometabolic		
	*	Design," J. Med. Chem 39 (24).		11 411 7	TY'-1. M1 1 127 ' 1. Y 1'		
	CQ 6	Ratner, R. E. et al., "Persistent C			High-Molecular Weight Insulin		
		Aggregates," Diabetes, 1990, 39	9:. /28 - 733.		and of Insulin Hains Dishatis		
11	CR Q	Robbins, D. C. et al., "Antibodic	es to Covale	ent Aggregates of Insulin in Bl	ood of insulin-Using Diabetic		
MA		Patients," Diabetes, 1987, 36: 8	536-841.	Oral Administration of Insulin	and Other Pentide Drugs "		
MA	CS &	Saffran, M. et al., "A New Appr		Oral Administration of Insulif	i and Onici repude Diugs,		
100	CT	Science, 1986, 233: 1081-1084	n with I Cl	utamic Acid for Brain Drug De	elivery," Proceed. Intern. Symp.		
	CT &	Sakaeda, T., et al., "Conjugation Control. Rel. Bioact. Mater., 19			onverg, rroccou. main. Symp.		
 	CU 6	Shashoua V.E., et al., "y-Amino			Jptake, and Pharmacological		
	000	Studies of Aliphatic and Steroid	l Esters of v	-Aminobutyric Acid." J. Med.	Chem., 1984, 27 (5): 660-664.		
 	CV 🔊	Shashoua, V.E., et al., "N-Doco	sahexaenoy	yl, 3 Hydroxytyramine: A Dopa	aminergic Compound that		
	R	Penetrates the Blood-Brain Barn	rier and Sup	opresses Appetite," Life Science	ces, 58 (16): 1347-1354.		
	CW	Sim, L., et al., "In vitro Autorad	diography of	f Receptor-Activated G Protein	ns in Rat Brain by Agonist-		
	.0	stimulated Guanylyl 5'-[γ[35S]th	nio]-Triphos	sphate Binding," Proc. Natl. A	cad. Sci., USA, 1995, 92: 7242-		
		7246.					
	CX v	Terasaki, T., et al., "Oligopeption	de Drug De	livery to the Brain," Amer. Ch	em. Soc. 1995; 297-316.		
	CY	Tsuzuki, N., et al., "Rabid Com	munication	. Adamantane as a Brain-Dire	cted Drug Carrier for Poorly		
	0	Absorbed Drug: Antinociceptiv	e Effects of	f [D-Ala²] Leu-Enkephalin Der	ivatives Conjugated with the 1-		
		Adamantane Mojety," Biochem	nical Pharma	acology, 1991, 41 (4): R5-R8.			
·	CZ 🍖	Wagner, J., et al., "Neuropharm	nacology of	Endogenous Opioid Peptides,'	' Psychopharmacology: The		
			1995: 519-5	529.			
	DA g	Weber, S.J., et al., "Distribution	n and Analg	gesia of ['H][D-PEN', D-PEN'	JENKephalin and Two		
		I Halogenated Analogs after Intra	avenous Ad	ministration," J. Pharm. Exper	. 1 ner., 1991, 209; 1109-1112.		
	DB	Weber, S.J., et al., "Whole Bod	y and Brain	1 Distribution of ["H]Cyclic [D	Pharm Eyper Ther 1992 263:		
	•		rai and Subc	cutaneous Auministration," J. I	Pharm. Exper. Ther., 1992, 263:		
[" '		1308-1316.					
	<u> </u>						
			Continue	on Page			
Examiner				DATE CONSIDERED			
	.0	(* 		skiloz			
	В	cecs A		l <u> </u>	D 0 000 -		
EXAMINER	: Initial	if citation considered, whether o	r not citatio	on is in conformance with MPE	P § 609; Draw line through		

citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO 4012-113 DIV2	SERIAL NO 09/430,735					
			APPLICANT		RECEI			
INFORMAT	INFORMATION DISCLOSURE STATEMENT			Ekwuribe et al.			RECEI	
(u	(use several sheets if necessary)			FILING DATE		GROUP	DEC 14	1999
İ				October 29, 1999	•	1639	TECH CENTER 16	422 /222
			U.S.	PATENT DOCUMENTS				00/290[
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
111	AA	4,585,754	29 Apr. 1986	Meisner et al.	514	8		
THE STATE OF THE S	AB	4,179,337	18 Dec. 1979	Davis et al.	435	181		
	AC	4,003,792	18 Jan. 1977	Mill et al.	195	63		
/IM	AD	4,849,405	18 Jul. 1989	Ecanow	NPE \	3		1
110	AE	5,013,556	7 May 1991	Woodle et al.	- 7 個多名			
MA	AF	4,963,367	16 Oct. 1990	Ecanow	424 8	782		1
M	AG	4,044,196	23 Aug. 1977	Hüper et al.	TRADEME	271		1
m	AH	4,717,566	5 Jan. 1988	Eckenhoff et al.	Y24	438		1
	AI	4,698,264	6 Oct. 1987	Steinke	428	40-2-2		1
THE STATE OF THE S	AJ	4,684,524	4 Aug. 1987	Eckenhoff et al.	424	469		1
M	AK	4,410,547	18 Oct. 1983	Ueno et al.	424	317		1
W/M	AL	3,256,153	14 Jun. 1966	Heimlich	167	82		
That	AM	4,935,246	19 Jun. 1990	Ahrens	424	490		
100	AN	4,797,288	10 Jan 1989	Sharma et al.	424	476		1
IM	AO	4,744,976	17 May 1988	Snipes et al.	424	408		1
M	AP	5,055,304	8 Oct. 1991	Makino et al.	424	465]
m	AQ	5,055,300	8 Oct. 1991	Gupta	424	409]
IM	AR	4,772,471	20 Sep. 1988	Vanlerberghe et al.	424	450]
m	AS	5,093,198	3 Mar. 1992	Speaker et al.	428	402,21		
Ma	AT	4,840,799	20 Jun. 1989	Appelgren et al.	424	4.93]
1/h	AU	4,622,392	11 Nov. 1986	Hong et al.	536	29		
M	AV	5,653,987	5 Aug. 1997	Modi et al.	424	607]
11/2	AW	5,792,834	11 Aug. 1998	Hakimi et al.	530	351]
1111	AX	5,595,732	21 Jan. 1997	Hakimi et al.	424	85.7	7	
1//	AY	5,539,063	23 Jul. 1996	Hakimi et al.	625	403		
				Continue on page 2				
EXAMINER	B	celsa				DATE CON		
EXAMINER citation if no	t: Initia	I if citation consi	dered, whether or ot considered. Inc	or not citation is in conformance clude copy of this form with ne	e with MPEP ext communic	§ 609; Draw cation to the ap	line through pplicant.	

FORM PTO-	1449	US Dept. of C		ATTORNEY DOCKET NO.		SERIAL NO			
		Patent and Tra	demark Office	4012-113 DIV2		09/430,735)		
				APPLICANT					
INFORMATI	ION DI	SCLOSURE STA	ATEMENT	Ekwuribe et al.					
(us	se sever	al sheets if neces	sary)	FILING DATE GROUP					
			October 29, 1999	1	16	,39			
EXAMINER INITIAL 7	1	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING I		
1/1	ΑZ	5,559,213	24 Sep 1996	Hakimi et al.	530	351)		
M	BA	5,747,646	5 May 1998	Hakimi et al.	530	351	-	٠ ـ ـ	
M	BB	5,286,637	15 Feb. 1994	Veronese et al.	PUSS	183		-	
M	BC	5,631,263	20 May 1997	Portoghese et al.	E.J.	279	_		
	BD	5,602,099	11 Feb. 1997	Schiller Schiller	7 1999 5	18	_		
11/1/2	BE	5,545,719	13 Aug. 1996	Shashoua et al.	5.30	345			
	BF	5,641,861	24 Jun. 1997	Shashoua et al. Dooley et al.	ARKO 30	329		-	
1///	BG	5,663,295	2 Sep. 1997	Moreau et al.	530	330		<u> </u>	
AC	ВН	5,786,447	28 Jul. 1998	Schiller et al.	531	307	7		
	BI	4,939,174	3 Jul. 1990	Shashoua	514	549		-	
11/1	BJ	5,932,462	Aug. 3, 1999	Harris et al.	435	188			
				ON PATENT DOCUMENTS			- an . Not		
		DOCUMENT	PUBLICATION				TRANSL	AHUN	
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
				COUNTRY	CLASS	SUBCLASS	YES		
		NUMBER	DATE				YES	NO	
- 11		NUMBER OTHER DOCU	DATE MENTS (Includ	ing Author, Title, Journal-Da	te, Page N	umber, Etc.)		NO X	
or .	BK &	NUMBER OTHER DOCU Alyautdin, R.N	DATE MENTS (Includ I., "Delivery of L		te, Page N	umber, Etc.) with Polysorb		NO X	
M		OTHER DOCU Alyautdin, R.N. Polybutylcyand Aoshima, M. e	MENTS (Includ I., "Delivery of L bacrylate Nanopa t al., "N ⁴ -Beheno	ing Author, Title, Journal-Da operamide Across the Blood-Br rticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto	te, Page Norain Barrier 4: 325-328	umber, Etc.) with Polysorb	pate 80-Coal	NO X	
	BK b	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researe	MENTS (Includ I., "Delivery of L pacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248	ing Author, Title, Journal-Da operamide Across the Blood-Br rticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto 1-2486.	te, Page Norain Barrier 4: 325-328 ssine as a Po	with Polysorb	ate 80-Coa	NO X ted gent,"	
	BK &	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G. Assoc. J. 1922	MENTS (Includ I., "Delivery of L pacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 et al., "Pancreat t, 12: 141-146.	ing Author, Title, Journal-Da operamide Across the Blood-Bi rticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto 1-2486. ic Extracts in the Treatment of I	rain Barrier 4: 325-328 sine as a Po	with Polysorb tential New A	ate 80-Coar Intitumor A	NO X ted gent,"	
M	BK b	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G. Assoc. J. 1922 Baker, D. C. et	MENTS (Includ I., "Delivery of L pacrylate Nanopa t al., "N ⁴ -Behence th, 1977, 37: 248 the et al., "Pancreat the included in the included in the included the included in the included in th	ing Author, Title, Journal-Da operamide Across the Blood-Br rticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto 1-2486. ic Extracts in the Treatment of I	rain Barrier 4: 325-328 sine as a Po	with Polysorb tential New A	ate 80-Coar Intitumor A	NO X ted gent,"	
M	BK &	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G. Assoc. J. 1922 Baker, D. C. et (O-Acyl) Deriv Banks, W.A., e	DATE MENTS (Includ I., "Delivery of L pacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 et al., "Pancreat 12: 141-146. al., "Prodrugs of vatives," J. Med. et al., "Passage of	ing Author, Title, Journal-Da operamide Across the Blood-Br rticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto 1-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-12: f Peptides Across the Blood-Bra	te, Page Norain Barrier 4: 325-328 sine as a Po Diabetes Mone. 1. Synth 21.	with Polysorb tential New A	nate 80-Coan Intitumor A Canadian Me	NO X ted gent,"	
	BK & BL & BM & BN & BO &	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G. Assoc. J. 1922 Baker, D. C. et (O-Acyl) Deriv Banks, W.A., e Perspectives,"	MENTS (Includ I., "Delivery of L pacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 et al., "Pancreat 12: 141-146. al., "Prodrugs of vatives," J. Med. et al., "Passage of Life Sciences, 19	ing Author, Title, Journal-Da operamide Across the Blood-Branticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto 1-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-122 f Peptides Across the Blood-Brane 196, 59 (23), 1923-1943.	te, Page Norain Barrier 4: 325-328 sine as a Po Diabetes Mone. 1. Synth 21. nin Barrier:	with Polysorb otential New A ellitus," The C esis and Evalu	eate 80-Coar antitumor A canadian Me nation of So	NO X ted gent," ed.	
	BK & BL & BM & BN &	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G. Assoc. J. 1922 Baker, D. C. et (O-Acyl) Deriv Banks, W.A., e Perspectives," Boccu, E. et al Pharm. Res. Ce	MENTS (Included)., "Delivery of Loacrylate Nanopatal., "N ⁴ -Behenoch, 1977, 37: 248, et al., "Pancreat, 12: 141-146. Et al., "Prodrugs of vatives," J. Med. et al., "Passage of Life Sciences, 19., "Pharmocokine form., 1982, 14:	ing Author, Title, Journal-Da operamide Across the Blood-Briticles," Pharm. Res. J., 1997, 1 yl-1-β-D-Arabinofuranosylcyto 1-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-122 f Peptides Across the Blood-Bra 196, 59 (23), 1923-1943. etic Properties of Polyethylene C 11-120.	rain Barrier 4: 325-328 sine as a Po Diabetes Me ne. 1. Synth 21. nin Barrier: Glycol Deriv	with Polysorb betential New A ellitus," The C esis and Evalu Pathophysiolo	anadian Melation of Sological	NO X ted gent," ed. me 5'-	
M	BK & BL & BM & BN & BO &	Alyautdin, R.N. Polybutyleyand Aoshima, M. e Cancer Researd Banting, R. G., Assoc. J. 1922 Baker, D. C. et (O-Acyl) Derive Banks, W.A., e Perspectives," Boccu, E. et al Pharm. Res. Ce Bodor, N., et a	MENTS (Included)., "Delivery of Loacrylate Nanopatal., "N ⁴ -Behenoch, 1977, 37: 248, et al., "Pancreat, 12: 141-146. Et al., "Prodrugs of vatives," J. Med. et al., "Passage of Life Sciences, 19., "Pharmocokine form., 1982, 14:	ing Author, Title, Journal-Da operamide Across the Blood-Braticles," Pharm. Res. J., 1997, 1 191-1-β-D-Arabinofuranosylcyto 11-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-12: F Peptides Across the Blood-Bratic Poperation of Polyethylene Control of Polyethylene Con	rain Barrier 4: 325-328 sine as a Po Diabetes Me ne. 1. Synth 21. nin Barrier: Glycol Deriv	with Polysorb betential New A ellitus," The C esis and Evalu Pathophysiolo	anadian Melation of Sological	NO X ted gent," ed. me 5'-	
M	BK & BL & BM & BN	Alyautdin, R.N. Polybutyleyand Aoshima, M. e Cancer Researd Banting, R. G., Assoc. J. 1922 Baker, D. C. et (O-Acyl) Derive Banks, W.A., e Perspectives," Boccu, E. et al Pharm. Res. Ce Bodor, N., et a	MENTS (Includ I., "Delivery of L bacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 et al., "Pancreat t, 12: 141-146. cal., "Prodrugs of vatives," J. Med. et al., "Passage of the Sciences, 19 the Sciences,	ing Author, Title, Journal-Da operamide Across the Blood-Braticles," Pharm. Res. J., 1997, 1 191-1-β-D-Arabinofuranosylcyto 11-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-12: F Peptides Across the Blood-Bratic Poperation of Polyethylene Control of Polyethylene Con	rain Barrier 4: 325-328 sine as a Po Diabetes Me ne. 1. Synth 21. nin Barrier: Glycol Deriv	with Polysorb betential New A ellitus," The C esis and Evalu Pathophysiolo	anadian Melation of Sological	NO X ted gent," ed. me 5'-	
Examiner	BK & BL & BM & BN	Alyautdin, R.N. Polybutyleyand Aoshima, M. e Cancer Researd Banting, R. G., Assoc. J. 1922 Baker, D. C. et (O-Acyl) Derive Banks, W.A., e Perspectives," Boccu, E. et al Pharm. Res. Ce Bodor, N., et a	MENTS (Includ I., "Delivery of L bacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 et al., "Pancreat t, 12: 141-146. cal., "Prodrugs of vatives," J. Med. et al., "Passage of the Sciences, 19 the Sciences,	ing Author, Title, Journal-Da operamide Across the Blood-Briticles," Pharm. Res. J., 1997, 1 byl-1-β-D-Arabinofuranosylcyto 12-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-122 f Peptides Across the Blood-Brain 1296, 59 (23), 1923-1943. etic Properties of Polyethylene C 11-120. or Delivering Peptides into the C 17, 1698-1702.	rain Barrier 4: 325-328 sine as a Po Diabetes Me ne. 1. Synth 21. nin Barrier: Glycol Deriv	with Polysorb otential New A cellitus," The C esis and Evalu Pathophysiolo vatized Superc rous System by	anadian Me anadian Me anadian of So gical oxide Dismu	NO X ted gent," ed. me 5'-	
	BK & BL & BM & BN	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G. Assoc. J. 1922 Baker, D. C. et (O-Acyl) Derive Banks, W.A., e Perspectives," Boccu, E. et al Pharm. Res. C. Bodor, N., et a Metabolism,"	MENTS (Includ I., "Delivery of L bacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 et al., "Pancreat t, 12: 141-146. cal., "Prodrugs of vatives," J. Med. et al., "Passage of the Sciences, 19 the Sciences,	ing Author, Title, Journal-Da operamide Across the Blood-Briticles," Pharm. Res. J., 1997, 1 byl-1-β-D-Arabinofuranosylcyto 12-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-122 f Peptides Across the Blood-Brain 1296, 59 (23), 1923-1943. etic Properties of Polyethylene C 11-120. or Delivering Peptides into the C 17, 1698-1702.	rain Barrier 4: 325-328 sine as a Po Diabetes Me ne. 1. Synth 21. nin Barrier: Glycol Deriv	with Polysorb betential New A cellitus," The C esis and Evalu Pathophysiolo vatized Superc	anadian Me anadian Me anadian of So gical oxide Dismu	NO X ted gent," ed. me 5'-	
B. EXAMINER	BK & BL & BN	Alyautdin, R.N. Polybutylcyand Aoshima, M. e Cancer Researd Banting, R. G., Assoc. J. 1922 Baker, D. C. et (O-Acyl) Derive Banks, W.A., e Perspectives," Boccu, E. et al Pharm. Res. Compartment	MENTS (Includ I., "Delivery of L bacrylate Nanopa t al., "N ⁴ -Beheno ch, 1977, 37: 248 , et al., "Pancreat , 12: 141-146. cal., "Prodrugs of vatives," J. Med. et al., "Passage of Life Sciences, 19 ., "Pharmocokine omm., 1982, 14: l., "A Strategy for Science, 1992, 25 dered, whether of	ing Author, Title, Journal-Da operamide Across the Blood-Briticles," Pharm. Res. J., 1997, 1 byl-1-β-D-Arabinofuranosylcyto 12-2486. ic Extracts in the Treatment of I f 9-β-D-Arabinofuranosyladenin Chem., 1978, 21(12): 1218-122 f Peptides Across the Blood-Brain 1296, 59 (23), 1923-1943. etic Properties of Polyethylene C 11-120. or Delivering Peptides into the C 17, 1698-1702.	te, Page Norain Barrier 4: 325-328 sine as a Po Diabetes Mo ne. 1. Synth 21. nin Barrier: Glycol Deriv Central Nerv	with Polysorbotential New Action Polysorbotential New Action Pathophysiology attized Supercous System by DATE CONTRACTOR SIGNATURE OF S	anate 80-Coanantitumor A Canadian Mediation of Sological Dixide Dismuy Sequential USIDERED Discounting through	NO X ted gent," ed. me 5'- utase,"	

FORM PTO-1449		US Dept. of Commerce	ATTORNEY DOCKET NO.	SERIAL NO.				
		Patent and Trademark Office		09/430,735				
			4012-113 DIV2					
			APPLICANT O	P 📉				
INFORMATION DISCLOSURE STATEMENT			Ekwuribe et al.					
(use several sheets if necessary)			FILING DATE	1999 Gr GROUP				
			October 29, 1999	(SA)				
			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	1639				
	BR	Bodor, N., et al., "Molecular Pa	ckaging. Peptide Delivery to The	Central Nervous System by Sequential				
M_1	Θ	Metabolism," Amer. Chem. Soc	e., 1995: 317-337					
ľ	BS &		bility of Insulin. 1. Hydrolytic Degradation During Storage of					
		Pharmaceutical Preparations," F	Pharm. Res., 1992, 9 (6): 715-726).				
	BT 0	Brange, J. et al., "Chemical Stat	oility of Insulin. 2. Formation of I	Higher Molecular Weight Transformation				
 		Products During Storage of Pha	rmaceutical Preparations," Pharm	Estragania Activity of a Prain Targeting				
	BU 🖡	Brewster, M.E., et al., "Effect o	t Molecular Manipulation on the stem," J. Med. Chem., 1994, 37:	Estrogenic Activity of a Brain-Targeting				
 	BV	Brauster M.F. et al "Efficacy	of a 3-Substituted Versus 17-Sul	ostitured Chemical Delivery System for				
	BV	Estradiol Brain Targeting," J. P						
<u> </u>	BW	Brewster, M., et al., "Tissue Dis	stribution of LY231617, an Antio	xidant with Neuroprotectant Activity, in				
ph		Brewster, M., et al., "Tissue Distribution of LY231617, an Antioxidant with Neuroprotectant Activity, in the Rat," J. Pharm. Studies," 1995, 84 (7): 791-793.						
M BX		Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res.,						
/ 199		1991, 8 (12): 1453-1459.						
			ary Excretion of the Model Opioi	d Peptide [D-PEN ^{2,2}] Enkephalin in Rats,"				
		Pharm. Res. J., 14: 343-330.	Dolivary of Enkanhalin Dantida	through Eyes " Life Sciences 1088 43.				
		Chiou, G.C.Y., et al., "Systemic 509-514.	mic Delivery of Enkephalin Peptide through Eyes," Life Sciences, 1988, 43:					
 	CA s	Chun W et al "Transmusoss	osal Delivery of Methionine Enkephalin. I: Solution Stability and Kinetics of					
\	CA \$	Degradation in Various Rabbit	Mucosa Extracts," J. Pharm.Sci.,	1993, 82 (4): 373-378.				
700	CB	Fix, J.A., "Oral Controlled Rele	ease Technology for Peptides: Sta	tus and Future Prospects," Pharm. Res.,				
		1996, 13 (12): 1760-1763.						
M	CC,	Gibson, A.M., et al., "Specificit	ity of Action of Human Brain Alanyl Aminopeptidase on Leu-Enkephalin					
-///	CD	and Dynorphin-Related Peptide	es," Neuropeptides, 1989, 13: 259-262.					
	CD 👠	Gish, D. T. et al., "Nucleic Acid Antileukemic and Immunosupp	ids. 11. Synthesis of 5'-Esters of 1-β-D-Arabinofuranosylcytosine Possessing pressive Activity," J. Med. Chem., 1971, 14(12): 1159-1162.					
 	CE	Hong, C. I. et al., "Nucleoside (Conjugates. 7. Synthesis and Anti	tumor Activity of 1-β-D-				
	\	Arabinofuranosylcytosine Conj	ugates of Ether Lipids," J. Med. C	Chem., 1986, 29: 2038-2044.				
	CF A	Horvat, J., et al., "Synthesis and	Biological Activity of [Leu ⁵] En	kephalin Derivatives Containing D-				
	V	Glucose," J. Peptide Protein Re	Res., 1988, 31: 499-507.					
CG by H		Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine						
		and Other Antiviral Nucleoside	s," The Journal of Biological Che	mistry, 1990, 265(11): 6112-6117.				
	CH 0	Kroll, R.A., et al., "Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and						
<u> </u>		Other Means," 1998 Neurosurgery, 42 (5): 1083-1100.						
	CI 🕖	Maislos, M. et al., "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is						
	CI	Therapeutic Insulin," J. Clin. Invest., 1986, 77: 717-723. Mosnaim, A.D., et al., "Studies of the in Vitro Human Plasma Degradation of Methionine-Enkephalin,"						
	Cl 😢	Mosnaim, A.D., et al., "Studies of the in Vitro Human Plasma Degradation of Methiorine-Enkephann, Gen. Pharmac., 1988, 19 (5): 729-733.						
	CK 10	Nestor, J., "Improved Duration	of Action of Peptide Drugs," Am	er. Chem Soc. 1995: 449-471.				
 				c Polymer-Conjugated Protein Drug,				
1/1/	CL 6	Smanes in an Oily Formulation	1," Pharm. Res., 1990, 7 (8): 852	-855.				
1111	1	Comanes, in an Ony I ormalation	Continue on Page 4					
F				DATE CONSIDERED				
Examiner	B	C CLSA		4/21/03				
EXAMINER	: Initia	if citation considered, whether of	or not citation is in conformance w	rith MPEP § 609; Draw line through				
-ia-ai iC	4 in and	formance and not considered. In	clude conv of this form with next	communication to the applicant.				

	-		, ,	1					
ORM PTO		U.S. Department nt and Trademark				cket Number 9233-8DV2		Serial No. 09/430,735	
LIST	OF DO	CUMENTS CITE	ED BY APPLI	CANT					
10									
70176		se several sheets if	necessary)		<u> </u>				
NOV 0 6 200	2 S				Applicants:	Ekwi	ribe et al.		
	<u></u>				Fili - D-4-		and cran.		
THE PATENT DO					Filing Date: October 29, 1999			Group 1627 - 16	
MUEMIN				S. PATENT DO	L			1927	
	Ĭ		T	I AIENI DO	COMENTS	T			
Examiner Initial		Document Number	Date	N	ame	Class	Subclass	Filing Date if	
	l							Appropriate	
MI	1.	5,681,811	10/28/97	Ekwuribe		514	8		
11/1/	2.	5,693,769	12/02/97	Kahne et al.		536	5	· 	
		1							
, 			ļ	 					
	<u> </u>		ļ	 	-Ar-	<u> </u>			
-			<u> </u>		REC. NOV.	*		-	
				7	Chi NOV	1//			
				`	OF CENT	9200	1		
					1 S. P. J. B.				
					o _e	PEDO			
	1	1	FORE	IGN PATENT I	OCUMENTS	<u> </u>			
	-	Document						Translation	
		Number	Date	Cor	untry	Class	Subclass	Yes No	
	I	OTHER DO	TID CENTER C	Landing A. B	Tide Det - P	<u> </u>	I		
	1	OTHER DOC	LUMENTS (li	ncluding Author	, Title, Date, Pe	rtinent Pages	, EIC.)		
									
			<u> </u>						

EXAMINER EXAMINER

B. ceisa

DATE CONSIDERED

5/21/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.